VIKING THERAPEUTICS INC (VKTX:NASDAQ)
$34.48 0.31 (0.9072%)
Analysed VIKING THERAPEUTICS INC (VKTX:NASDAQ) News Sources
LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?
13-08-2026
yahoo.com
LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?
17-08-2026
yahoo.com
How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's?
19-08-2026
yahoo.com
VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t
30-07-2026
stocktwits.com
VKTX Launches $500M Shelf After Full Enrollment Of Phase 3 Obesity Drug Study – Retail Bets On ‘Exceptionally Great Data’
30-07-2026
stocktwits.com
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target
30-07-2026
fool.com
Viking Therapeutics' VK2735 Drives Substantial Optionality, Oppenheimer Says
03-08-2026
yahoo.com
Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished
06-08-2026
fool.com
Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?
08-08-2026
fool.com
2 GLP-1 Stocks That Could Double Your Money by 2031
16-08-2026
fool.com
What is the current price of VIKING THERAPEUTICS INC (VKTX:NASDAQ)?
The current price of VIKING THERAPEUTICS INC (VKTX:NASDAQ) is $34.48.
VIKING THERAPEUTICS INC (VKTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of VIKING THERAPEUTICS INC (VKTX:NASDAQ) since the previous trading day is $0.31.
VIKING THERAPEUTICS INC (VKTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of VIKING THERAPEUTICS INC (VKTX:NASDAQ) since the previous trading day is 0.9072%.
What is the most recent average sentiment score for VIKING THERAPEUTICS INC (VKTX:NASDAQ)?
The most recent average sentiment score for VIKING THERAPEUTICS INC (VKTX:NASDAQ) is 68 out of 100.
What is the most recent average sentiment for VIKING THERAPEUTICS INC (VKTX:NASDAQ)?
The most recent sentiment for VIKING THERAPEUTICS INC (VKTX:NASDAQ) is .
SEC-8K** Filing Available For VIKING THERAPEUTICS INC (VKTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.